RBC Capital Markets acted as Joint Lead Arranger, Joint Bookrunner and Documentation Agent on debt financing of $750 million to fund the acquisition of Axcan Pharma, Inc. by TPG Capital and its affiliates

Transaction Information RBC Capital Markets acted as Joint Lead Arranger, Joint Bookrunner and Documentation Agent on the senior secured credit facilities to fund the acquisition of Axcan Pharma, Inc. by TPG Capital and its affiliates for a total value of $1.3 billion, which consisted of a $115 million Senior Secured Revolving Credit Facility and a $175 million Senior Secured Term Loan, and acted as Joint Bookrunner on the bond offerings, which consisted of $225 million Senior Secured Notes and $235 million Senior Unsecured Notes. About Axcan Pharma Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and Europe.

About TPG Capital

TPG Capital is the global buyout group of TPG, a leading private investment firm founded in 1992, with more than $35 billion of assets under management. TPG Capital has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, joint ventures and restructurings. TPG Capital invests globally in companies in the healthcare, technology, financial services, consumer products, media and communications and industrial industries.

Summary Terms

Revolver:	$115 million (6-year)
Term Loan:	$175 million (6-year)
Senior Secured Notes:	$225 million (7-year)
Senior Unsecured  Notes:	$235 million (8-year)

Investment Banking Contacts

Andy Singer
Managing Director, Biotechnology

415-633-8537
andrew.singer@rbccm.com

Daniel Schnurman

Director, Specialty Pharmaceuticals

212-428-6310

daniel.schnurman@rbccm.com